Q-omics provides the consensus-scored PAM16 profile across patient tissues and cancer cell-line models. PAM16 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PAM16 is differentially expressed in 17, with the highest sampling consensus in KIRC. Additionally, PAM16 RNA expression shows 17,565 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRC as cancer lineages where PAM16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PAM16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PAM16 survival associations across molecular data types. PAM16 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PAM16 RNA expression–survival associations across cancer types. High PAM16 expression shows unfavorable associations in UVM, KIRC, SCLC, KIRP and PRAD, but favorable associations in BLCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PAM16 RNA expression.
This table summarizes PAM16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PAM16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PAM16 shows higher tumor expression in KIRC, COAD, KIRP, HNSC, LIHC and STAD. The KIRC box plot shows higher PAM16 RNA expression in tumor versus normal tissue (log2 FC = +0.744, t-test p < 0.001).
This table shows molecular features associated with PAM16 in patient tissues and cancer cell lines. In patient samples, PAM16 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PAM16 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
